Inventiva (CHIX:IVAP) Other Current Payables: €5.47 Mil (As of Dec. 2025)


CHIX:IVAP Inventiva SA CHIX:IVAP
53 GF Score
Price €3.06
GF Value €0.24
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Inventiva Other Current Payables?

Inventiva CHIX:IVAP 53 Other Current Payables is €5.47 Mil as of Dec. 2025. GuruFocus rates CHIX:IVAP with a GF Score™ of 53/100 and a GF Value™ of €0.24 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Inventiva's Other Current Payables for the quarter that ended in Dec. 2025 was €5.47 Mil.

Inventiva's quarterly Other Current Payables increased from Dec. 2024 (€2.94 Mil) to Jun. 2025 (€6.30 Mil) but then declined from Jun. 2025 (€6.30 Mil) to Dec. 2025 (€5.47 Mil).

Inventiva's annual Other Current Payables increased from Dec. 2023 (€1.89 Mil) to Dec. 2024 (€2.94 Mil) and increased from Dec. 2024 (€2.94 Mil) to Dec. 2025 (€5.47 Mil).

Inventiva Other Current Payables Related Terms

Inventiva Other Current Payables Historical Data

* Premium members only.

The historical data trend for Inventiva's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inventiva Other Current Payables Chart

Inventiva Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Payables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.50 1.88 1.89 2.94 5.47

Inventiva Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.89 1.75 2.94 6.30 5.47
CHIX:IVAP
53GF Score
Inventiva SA CHIX:IVAP
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Inventiva Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of €5.47 Mil mean?
Inventiva (CHIX:IVAP) has a Other Current Payables of €5.47 Mil as of Dec. 2025. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Inventiva and its competitors.
Is Inventiva's Other Current Payables too high?
Inventiva's current Other Current Payables is €5.47 Mil. Overall, Inventiva has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Inventiva's Other Current Payables compare to VRTX and REGN?
Inventiva's Other Current Payables of €5.47 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Biotechnology company?
A good Other Current Payables depends on the Biotechnology industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Inventiva and its competitors. Inventiva's current Other Current Payables is €5.47 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inventiva stock overvalued right now?
Based on GuruFocus' analysis, Inventiva (CHIX:IVAP) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.24, compared to a current price of €3.06 — trading 1175% above its estimated fair value. The current Other Current Payables is €5.47 Mil. Inventiva's overall GF Score™ is 53/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Inventiva (CHIX:IVAP), the current Other Current Payables is €5.47 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Inventiva (CHIX:IVAP) Overvalued in 2026?

Based on GuruFocus' analysis, Inventiva stock appears to be overvalued. The current stock price of €3.06 is trading 1175% above its estimated GF Value™ of €0.24. GuruFocus considers Inventiva to be Significantly Overvalued.

Key valuation signals for CHIX:IVAP:

  • Other Current Payables: €5.47 Mil
  • GF Value™: €0.24 vs. price of €3.06 (1175% above fair value)
  • GF Score™: 53/100 with 7 warning signs

No single metric tells the full story. See the CHIX:IVAP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Inventiva Business Description

Address 50 rue de Dijon, Daix, FRA, 21121
Inventiva SA is a France-based clinical-stage biopharmaceutical company focused on the development of oral small-molecule therapies for the treatment of MASH. The wholly-owned research and development facility and a team with expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging the expertise, the company is also advancing lanifibranor for the treatment of MASH and has a pipeline of earlier-stage therapeutic programs in oncology. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France.
53GF Score

Get the complete analysis for CHIX:IVAP

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.06
Price
€0.24
GF Value